Antiretroviral therapy coverage in Liberia
Liberia: Antiretroviral therapy coverage was 86.0% in 2024. ◆ Volatile
Antiretroviral therapy coverage in Liberia, 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of people living with HIV.
Analysis
The most recent figure for antiretroviral therapy coverage in Liberia is 86.0%, measured in 2024. That is the highest value across all 25 years on record.
Compared with earlier readings it is up 17.8% on the previous year and up 437.5% over ten years.
Over the whole period, antiretroviral therapy coverage in Liberia peaked at 86.0% in 2024 and was at its lowest, 0.0%, in 2000.
That places Liberia 33rd out of 143 countries with data for 2024, putting it in the top quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage in Liberia, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 0.0% | — |
| 2004 | 0.0% | — |
| 2005 | 0.0% | — |
| 2006 | 2.0% | — |
| 2007 | 3.0% | +50.0% |
| 2008 | 4.0% | +33.3% |
| 2009 | 7.0% | +75.0% |
| 2010 | 10.0% | +42.9% |
| 2011 | 13.0% | +30.0% |
| 2012 | 12.0% | -7.7% |
| 2013 | 15.0% | +25.0% |
| 2014 | 16.0% | +6.7% |
| 2015 | 18.0% | +12.5% |
| 2016 | 20.0% | +11.1% |
| 2017 | 30.0% | +50.0% |
| 2018 | 36.0% | +20.0% |
| 2019 | 41.0% | +13.9% |
| 2020 | 49.0% | +19.5% |
| 2021 | 57.0% | +16.3% |
| 2022 | 67.0% | +17.5% |
| 2023 | 73.0% | +9.0% |
| 2024 | 86.0% | +17.8% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 1.6% | 0.0% | 7.0% | 10 |
| 2010s | 21.1% | 10.0% | 41.0% | 10 |
| 2020s | 66.4% | 49.0% | 86.0% | 5 |
Countries ranked near Liberia
- 33 Azerbaijan 86.0% compare
- 33 Italy 86.0% compare
- 33 Sierra Leone 86.0% compare
- 33 Singapore 86.0% compare
- 33 Slovenia 86.0% compare
More health data for Liberia
- Un projection of annual infant deaths, annual growth rate -1.57 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.7528 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,097 deaths per 1,000 people (2090)
- Number of infants who die before age 1 3,457 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 7 (2025)
- Population ages 00-04, female, annual growth rate 1.13 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0.0001 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.068 units per person (2025)
- Population ages 00-04, male, annual growth rate 1.13 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0.0001 units per US$ of GDP (2025)
Frequently asked questions
- What is antiretroviral therapy coverage in Liberia?
- Antiretroviral therapy coverage in Liberia was 86.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage recorded in Liberia?
- The highest recorded value was 86.0% in 2024.
- What is the lowest antiretroviral therapy coverage recorded in Liberia?
- The lowest recorded value was 0.0% in 2000.
- How does Liberia rank for antiretroviral therapy coverage?
- Liberia ranks 33rd out of 143 countries with data for 2024.
- Is antiretroviral therapy coverage rising or falling in Liberia?
- Over the last ten years it is up 437.5%. The long-run trend across the full record is volatile.
- Where does this Liberia data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage (% of people living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.